Novartis stock rose Friday after the drugmaker beat fourth-quarter expectations, largely on the back of its heart failure drug Entresto.

Swiss drug-major Novartis AG reported Friday weak net earnings in its fourth quarter on the absence of prior year's significant gain ...

Novartis AG (NYSE:NVS) shares are trading higher in the premarket session on Friday. The Swiss pharma giant reported ...

Novartis (NVS) reported $13.15 billion in revenue for the quarter ended December 2024, representing a year-over-year increase of 15.1%. EPS of $1.98 for the same period compares to $1.53 a year ago.

J.P. Morgan analyst Richard Vosser has maintained their neutral stance on NOVN stock, giving a Hold rating today.Invest with Confidence: ...

AbbVie and Novartis to report Q4 earnings. AbbVie in stagnating trend, Novartis bullish. Breakdown of technical charts. Novartis has advantage, investors watch for post-earnings movement.

Novartis was among the most prolific pharma dealmakers in 2024, a trend that it expects to continue with more bolt-on deals this year to set up for sustainable long-term growth.

In the corporate sector, Novartis (SIX: NOVN) stock rose 4% after Swiss drugmaker reported strong fourth-quarter results ...

Looking ahead to 2025, Novartis maintains an optimistic stance, forecasting mid to high single-digit sales growth and anticipating even stronger operational core earnings in the high single to low ...

Novartis AG (NVS) on Friday reported fourth-quarter net income of $2.82 billion. On a per-share basis, the Basel, Switzerland-based company said it had net income of $1.41. Earnings, adjusted for ...

At prices below $100 per share, Novartis stock is an attractive buy, but investors need patience due to potential short-term revenue declines. With a dividend yielding nearly 3%, manageable debt ...